av/in8bio-inc--big.svg

NASDAQ:INAB

IN8bio, Inc.

  • Stock

USD

Last Close

1.66

06/11 21:40

Market Cap

37.34M

Beta: -

Volume Today

484.98K

Avg: 3.83M

PE Ratio

−1.32

PFCF: −1.90

OverviewFinancialsAPI

    Description

    IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; a...Show More

    Excel Tearsheet

    Earnings

    Earnings per Share (Estimate*)

    -0.5-0.4-0.3-0.2-0.12018-03-302019-06-302021-03-312023-03-302024-04-04

    Revenue (Estimate*)

    0.000.000.010.010.012018-03-302019-06-302021-03-312023-03-302024-04-04

    *Estimate based on analyst consensus